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Virus-associated hemophagocytic syndrome is a fulminant dis-
order associated with systemic viral infection and characterized
pathologically by multiple-organ infiltration of hemophagocytic
histiocytes into the lymphoreticular tissues. This is the first
report of a previously healthy adult in whom Human herpesvirus
6 reactivation induced this syndrome with severe hemodynamic
and respiratory distress.
irus-associated hemophagocytic syndrome (VAHS) is a
fulminant disorder associated with systemic viral infec-
tion and characterized pathologically by multiple-organ infil-
tration of hemophagocytic histiocytes into the lymphoreticular
tissues. VAHS has been associated with  Epstein-Barr virus
(EBV), cytomegalovirus (CMV), adenovirus, and Herpes sim-
plex virus (HSV), as well as with a variety of nonviral infec-
tions (1). There have been several reports of VAHS in children
caused by Human herpesvirus 6 (HHV-6) infection. We report
what may be the first record of reactivated HHV-6 causing
VAHS with severe hemodynamic and respiratory distress in a
previously healthy adult.
Case Report
A healthy 22-year-old man with a high fever lost con-
sciousness and was admitted to our hospital. On admission, a
skin rash covered his whole body; cervical, axial, inguinal, and
supraclavicular lymphadenopathy and hepatosplenomegaly
were observed. The leukocyte count was 14,590/mm3, the
hemoglobin concentration 13.9 g/dL, and platelet count
12.7x104/mm3. Elevated liver enzymes (glutamate oxalacetic
transaminase 155 U/L, glutamate pyruvate transaminase 379
U/L) were found, along with elevated lactate dehydrogenase
911 U/L (normal 130-290 U/L) and C-reactive protein 4.9 mg/
dL (normal <0.2 mg/dL). Serum antibody tests for CMV and
HSV were negative, but a serum antibody test for EBV was
positive (1:640) on day 2 after admission. Infectious mononu-
cleosis was suspected, and the case was managed conserva-
tively without antibiotics for 13 days after admission.
On day 14, the patient suddenly went into shock and severe
respiratory distress developed, with PaO2 45 mmHg and
PaCO2 35 mmHg at FiO2 of 100%. Pancytopenia was evident,
with a leukocyte count of 270/mm3, hemoglobin of 9.1 g/dL,
and platelet count of 9.7x104/mm3 (Figure 1). The patient’s
bone marrow was hypocellular, with a nucleated cell count of
1.6x104/mm3 (normal 13.7-23.1x104/mm3), and showed an
increased number of histiocytes with hemophagocytosis and
mature large granulolymphocytes. Elevated serum concentra-
tions of tumor necrosis factor (TNF)-alpha (44 pg/mL; normal
<15.6 pg/mL), interleukin (IL)-12 (129 pg/mL; normal <3.9
pg/mL), IL-6 (3,415 pg/mL; normal <3.1 pg/mL), IL-8 (15,598
pg/mL; normal <31.2 pg/mL), and granulocyte-colony stimu-
lating factor (G-CSF) (165,000 pg/mL; normal <39.1 pg/mL)
were observed. Blood and organ bacteria cultures were nega-
tive. The CD4/CD8 ratio (0.73; normal 0.88-1.84) was low,
and complete suppression of immunoglobulin was observed,
with decreased immunoglobulin (Ig) A (30 mg/dL; normal
115-440 mg/dL), IgG (620 mg/dL; normal 1,000-2,060 mg/
dL), and CD19 (1.1%; normal 9.7-17.3 %). Serum antibody
tests for HHV-6 were positive (1:80 on day 7 and 1:280 on day
30 after admission), suggesting that this was a case of HHV-6
reactivation. HHV-6B was isolated as previously described (2)
from peripheral blood mononuclear cells (PBMC) on day 5
after admission (Figure 2), suggesting VAHS induced by
HHV-6. 
On day 14 after admission, at the onset of pancytopenia,
subcutaneous administration of recombinant human G-CSF
(Lenograstim; Chugai Pharmaceutical Co. LTD., Tokyo,
Japan) was started at 2 µg/kg. Improvement in hematologic
parameters was apparent 8 days after the start of G-CSF, and
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Figure 1. Changes in leukocyte count (solid circles), platelet count
(solid squares), and serum antibodies tests for Human herpesvirus 6
(HHV-6),  Herpes simplex virus (HSV), cytomegalovirus (CMV), and
Epstein-Barr virus (EBV) after admission. Values in the box demon-
strate immunoreactivity to HHV6, HSV, CMV, and EBV. aHHV-6B was
isolated from peripheral blood mononuclear cells on day 5 after admis-
sion. bPancytopenia was diagnosed on the day 14 after admission. IgG
= immunoglobulin G; G-CSF = granulocyte-colony stimulating factor
(G-CSF).88 Emerging Infectious Diseases  •  Vol. 8, No. 1, January 2002
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there were no further complications (Figure 1). With mechani-
cal ventilation and fluid resuscitation with catecholamine, the
respiratory and hemodynamic status improved. HHV-6B was
not isolated from PBMC on day 32 after admission. The symp-
toms and signs of VAHS disappeared completely, and the
patient was discharged 44 days after admission. 
Conclusions
VAHS is characterized by prominent phagocytosis of
erythrocytes and nucleated blood cells in the bone marrow and
lymph nodes. The general symptoms are fever and hepatosple-
nomegaly. Some cases have been been associated with hyper-
cytokinemia by TNF-alpha, IL-1-beta, and interferon (IFN-
gamma), resulting in severe hemodynamic collapse and acute
lung injury (3). Lymphocyte activation induces excessive pro-
duction of IFN-gamma, which acts on a variety of cells, result-
ing in macrophage activation and tissue damage. In keeping
with this proposed injury mechanism, successful treatment
with cyclosporin A has been documented (3). We administered
G-CSF alone, although the serum G-CSF concentration was
markedly increased when VAHS was diagnosed, suggesting
remarkable up-regulation. HHV-6 is a lymphotropic virus that
grows in PBMC. It is widespread in the normal population;
>80% of the general population in Japan is seropositive. Exan-
thema subitum has been considered a manifestation of primary
infection with HHV-6 (2). There have been several reports of
VAHS in children caused by HHV-6 infection (4,5). The few
adults who escape HHV-6 infection during childhood and
acquire primary HHV-6 infection as young adults have a self-
limited, febrile illness, usually associated with lymphadenopa-
thy and resembling infectious mononucleosis (6). To our
knowledge, this is the first report of a healthy adult in whom
HHV-6 reactivation induced VAHS with severe hemodynamic
and respiratory distress.
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Figure 2. Immunofluorescence micrograph of peripheral blood mononu-
clear cells infected with Human herpesvirus 6B isolated on day 5 after
admission. 
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